Cervical cancer and COVID-an assessment of the initial effect of the pandemic and subsequent projection of impact for women in England: A cohort study.

OBJECTIVE: To review the effect of the COVID-19 pandemic on the diagnosis of cervical cancer and model the impact on workload over the next 3 years. DESIGN: A retrospective, control, cohort study. SETTING: Six cancer centres in the North of England representing a combined population of 11.5 million. METHODS: Data were collected retrospectively for all diagnoses of cervical cancer during May-October 2019 (Pre-COVID cohort) and May-October 2020 (COVID cohort). Data were used to generate tools to forecast case numbers for the next 3 years. MAIN OUTCOME MEASURES: Histology, stage, presentation, onset of symptoms, investigation and type of treatment. Patients with recurrent disease were excluded. RESULTS: 406 patients were registered across the study periods; 233 in 2019 and 173 in 2020, representing a 25.7% (n = 60) reduction in absolute numbers of diagnoses. This was accounted for by a reduction in the number of low stage cases (104 in 2019 to 77 in 2020). Adding these data to the additional cases associated with a temporary cessation in screening during the pandemic allowed development of forecasts, suggesting that over the next 3 years there would be 586, 228 and 105 extra cases of local, regional and distant disease, respectively, throughout England. Projection tools suggest that increasing surgical capacity by two or three cases per month per centre would eradicate this excess by 12 months and 7 months, respectively. CONCLUSIONS: There is likely to be a significant increase in cervical cancer cases presenting over the next 3 years. Increased surgical capacity could mitigate this with little increase in morbidity or mortality. TWEETABLE ABSTRACT: Covid will result in 919 extra cases of cervical cancer in England alone. Effects can be mitigated by increasing surgical capacity.

UK health professionals' attitudes and knowledge regarding Human Papillomavirus (HPV) vaccination: a West Yorkshire Study.

AIM: To investigate the willingness of clinicians to recommend human papillomavirus (HPV) vaccination, the strength of support for a national HPV vaccine programme and to determine which factors, if any, affected these. METHODS: An online, invitation-only questionnaire was developed and distributed to three medical professional groups in the West Yorkshire Region, United Kingdom. RESULTS: Two hundred twenty-two responders were included in the final analysis, from the following specialties: general practice (62), paediatrics (103) and obstetrics and gynaecology (57). The majority of doctors were in favour of an National Health Service-funded national vaccination programme. Over 90% supported vaccination of girls as early as ages 11-13. Fewer doctors felt comfortable recommending vaccination to parents of girls under 16 than to young women. Latent class analysis demonstrated that doctors' self-rated knowledge of the HPV vaccine was an important determinant of willingness to recommend vaccination. Younger, more recently qualified doctors were less likely to be willing to recommend vaccination. CONCLUSIONS: There is widespread support for vaccination. Information provision to doctors will be important in maximising clinician confidence in recommending vaccination, and may be most beneficial when targeted at more junior doctors.